Exelixis Newsroom

Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)

TipRanksApr 30 04:23 ET

William Blair Maintains Exelixis(EXEL.US) With Buy Rating

Moomoo NewsApr 29 02:38 ET

Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), ImmunityBio (IBRX) and Exelixis (EXEL)

TipRanksApr 28 11:57 ET

JMP Securities Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $41

Moomoo NewsApr 18 01:35 ET

Guggenheim Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $42

Moomoo NewsApr 10 01:35 ET

Exelixis (EXEL) Gets a Buy From RBC Capital

TipRanksApr 4 21:54 ET

Guggenheim Remains a Buy on Exelixis (EXEL)

TipRanksMar 30 10:09 ET

Truist Financial Maintains Exelixis(EXEL.US) With Buy Rating

Moomoo NewsMar 28 01:32 ET

Exelixis Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow JonesMar 27 06:58 ET

Exelixis Analyst Ratings

BenzingaMar 27 06:48 ET

Citi Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $45

Moomoo NewsMar 27 01:31 ET

JMP Securities Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $41

Moomoo NewsMar 27 01:31 ET

Exelixis Gains Buy Rating From Silvan Tuerkcan Following Early FDA Approval and Growth Potential in Neuroendocrine Tumor Market

TipRanksMar 26 13:36 ET

BofA Securities Maintains Exelixis(EXEL.US) With Hold Rating, Maintains Target Price $39

Moomoo NewsMar 20 01:32 ET

RBC Capital Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $40

Moomoo NewsMar 14 01:32 ET

Truist Financial Maintains Exelixis(EXEL.US) With Buy Rating

Moomoo NewsMar 14 01:32 ET

Exelixis Is Maintained at Outperform by RBC Capital

Dow JonesMar 13 13:13 ET

Exelixis Analyst Ratings

BenzingaMar 13 13:03 ET

Analysts Are Bullish on Top Healthcare Stocks: Werewolf Therapeutics (HOWL), Exelixis (EXEL)

TipRanksMar 13 08:57 ET

Exelixis Analyst Ratings

BenzingaFeb 24 06:08 ET